Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KLK2

KLK2

Basics

Aliases:
This biomarker is also known as:
  • kallikrein-related peptidase 2,
  • Kallikrein-2,
  • MGC12201,
  • kallikrein 2, prostatic,
  • KLK2A2,
  • Tissue kallikrein-2,
  • Glandular kallikrein-1,
  • hGK-1,
  • hK2,
  • glandular kallikrein 2,

View in BioMuta

Description…

The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. The glandular kallikrein gene family comprises 25 to 30 highly homologous genes that encode specific proteases involved in the processing of biologically active peptides (they cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin). Several human kallikrein genes have been isolated.

Attributes

QA State: Accepted
Type: Protein
Short Name:
HGNC Name: KLK2

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Two
QA State: Accepted

Overview

Human glandular kallikrein (hK2) has been shown to add important information regarding the early detection and staging of prostate cancer. Together with percent free PSA (%fPSA), hK2 may help to distinguish preoperatively between pT2 and pT3 prostate cancer.

Performance Comment

hK2, hK4 and hK11 do not distinguish cases from controls in these populations.

Supporting Study Data

The following studies/protocols provide evidence supporting KLK2 indications for the Prostate…

Prostate Rapid Pre-Validation Set

Determine which markers move to validation using the prospectie prostate reference set samples.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Prostate Rapid Reference Set Application: Eleftherios Diamandis - Mt Sinai (2006)

No abstract available.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing cases with Gleason grade >=7 (n=30) to the pool of controls and cases with Gleason grade <7 (n=93), the AUC was 0.63 (0.52, 0.75). No specific cutoff was preselected for this analysis. N/A N/A N/A N/A N/A
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.59 (0.48, 0.69). No specific cutoff was preselected for this analysis. N/A N/A N/A N/A N/A
Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.